CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$47.72 USD
+0.17 (0.36%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $47.72 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.72 USD
+0.17 (0.36%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $47.72 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Vertex (VRTX) to Post Q2 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex's (VRTX) second-quarter earnings call, investor focus will be on the adoption of its newest CF drug Symdeko and the update on its NDA filing for the VX-445 triple combination regimen.
Can We Find The Right Stock Using Our Newly Found Insight?
by Panel Of Zacks Experts
Can We Find The Right Stock Using Our Newly Found Insight?
Should You Pick Up Novartis (NVS) Before Q2 Earnings?
by Mitchell Moore
Novartis AG (NVS) gained 1.1% so far in trading this week. Plus, the Swiss multinational pharmaceutical company has been on a tear since the end of April, up 18.2%. Now let's see what investors should expect heading into its Q2 2019 earnings release on Thursday.
Novartis' (NVS) Crizanlizumab Gets Priority Review From FDA
by Zacks Equity Research
The FDA accepts Novartis' (NVS) BLA for crizanlizumab and grants Priority Review to the same to prevent pain crises in patients with sickle cell disease.
Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
CRISPR Therapeutics Up on Collaboration Expansion by Vertex
by Zacks Equity Research
CRISPR Therapeutics (CRSP) is set to receive $175 million in upfront payment from Vertex following the expansion of the collaboration agreement for gene editing program to include new disease areas.
Vertex Expands Collaboration With CRISPR, Acquires Exonics
by Zacks Equity Research
Vertex (VRTX) is expanding its gene editing pipeline into new disease areas by expanding collaboration with CRISPR Therapeutics and acquiring Exonics.
Vertex Selects Triple Combo Regimen for Regulatory Submission
by Zacks Equity Research
Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.
Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Vertex (VRTX) beats on both earnings and sales in Q1 with demand for its newest CF drug, Symdeko, rising high.
What's in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
On Vertex's (VRTX) first-quarter earnings call, investor focus will be on its latest CF drug Symdeko's sales figure as well as the update on its CF triple-pill regimes.
Vertex, CRISPR's Gene Editing Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for a second indication - transfusion-dependent beta thalassemia.
Biotech ETFs Jump on Roche-Spark Deal
by Sweta Killa
The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.
CRISPR Therapeutics Up as Dosing Starts in Thalassemia Study
by Zacks Equity Research
CRISPR Therapeutics (CRSP) and partner Vertex start dosing of beta thalassemia patients in an early-stage study evaluating gene editing therapy, CTX001. Initiates enrollment in sickle cell disease study.
Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales
by Zacks Equity Research
Vertex's (VRTX) Q4 grows on earnings and revenue beat with rising demand for its CF products. Shares up.
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.
Vertex Terminates COO Ian Smith on Code of Conduct Violation
by Zacks Equity Research
Vertex (VRTX) announces termination of its chief operating officer, Ian Smith, owing to violation of the company's code of conduct and values.
Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for the treatment of sickle cell disease.
Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint
by Zacks Equity Research
Vertex (VRTX) reports positive phase II data of its pipeline candidate VX-150 in patients with pain caused by small fiber neuropathy.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $38.33, marking a -1.01% move from the previous day.
CRISPR Therapeutics AG (CRSP) Stock Moves -0.55%: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $36.17, moving -0.55% from the previous trading session.
Spectrum (SPPI) Earnings and Sales Beat Estimates in Q3
by Zacks Equity Research
Spectrum (SPPI) reports narrower-than-expected loss in the third quarter and also beats on revenues. The company is on track to file a BLA for Rolontis by year end.
Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (CRSP) Outperforming Other Medical Stocks This Year?
CRISPR THERAPTC (CRSP) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
CRISPR THERAPTC (CRSP) delivered earnings and revenue surprises of -44.59% and -83.91%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Cronos (CRON) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when Cronos (CRON) reports third-quarter results.
CRISPR THERAPTC (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
CRISPR THERAPTC (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.